TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection

Trial Profile

TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Rifapentine (Primary) ; Isoniazid
  • Indications Tuberculosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVENT TB
  • Most Recent Events

    • 18 May 2016 Results of post-hoc analysis of two phase III studies (PREVENT TB and iAdhere) presented at the 112th International Conference of the American Thoracic Society
    • 17 Mar 2016 Results published in the AIDS
    • 04 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top